



NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, CANADA, THE UNITED KINGDOM, HONG KONG, RUSSIA, BELARUS, SWITZERLAND, SINGAPORE OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES THAN SUCH MEASURES WHICH FOLLOWS FROM SWEDISH REGULATIONS.

The subscription period in Alzinovas rights issue of shares starts today

Today, April 17, 2025, the subscription period begins in Alzinova AB's (publ) ("Alzinova" or the "Company") rights issue of shares which the board of directors resolved on April 2, 2025 (the "Rights Issue"). The subscription period in the Rights Issue runs from and including April 17, 2025, up to and including May 6, 2025. However, note that some banks and nominees may have an earlier deadline for subscription in the Rights Issue. Shareholders should therefore check with their bank or nominee if they have an earlier deadline for subscription.

Summary of the Rights Issue:

- The Rights Issue comprises a maximum of 17,833,092 shares. If fully subscribed, the Rights Issue will provide Alzinova with approximately SEK 35.7 million before issuing costs.
- The right to subscribe for new shares in the Rights Issue shall be granted to shareholders with preferential rights in proportion to the number of shares they already own, whereby one (1) existing share as of the record date on April 15, 2025 entitled the holder to one (1) subscription right, and five (5) subscription rights entitle the holder to subscribe for one (1) new share.
- The subscription price per share in the Rights Issue amounts to SEK 2.0.
- The subscription period for the Rights Issue runs from and including April 17, 2025 up to and including May 6, 2025.
- The Rights Issue is covered to approximately 16.4 percent by subscription commitments, amounting to SEK 5.9 million, and to approximately 68.6 percent by underwriting commitments, amounting to SEK 24.5 million. Thus, the Rights Issue is covered to 85 percent through subscription commitments and underwriting commitments.

Estimated timetable for the Rights Issue



April 17 – April 30, 2025	Trading in subscription rights
April 17 – May 6, 2025	Subscription period
April 17 – May 26, 2025	Trading in BTA (paid subscribed shares)
May 8, 2025	Estimated date for the announcement of the outcome of the Rights Issue

Subscription with preferential rights

The shareholders who, on the record date of April 15, 2025, were registered in the share register maintained by Euroclear Sweden AB ("Euroclear") and on behalf of the Company, directly registered shareholders, receive a pre-printed issue report with attached payment advice from Euroclear. In the event that a different number of subscription rights than those stated in the preprinted issue report are used for subscription the special application form, which is available on the Company's website www.alzinova.com, shall be used as a basis for subscription through cash payment.

Shareholders whose holdings of shares in the Company were nominee-registered with a bank or other nominee on the record date do not receive an issue report or a special application form from Euroclear. Subscription and payment must then instead take place in accordance with instructions from the respective trustee.

Subscription without preferential rights

Notification of subscription without preferential rights by a nominee is made in accordance with instructions from the respective nominee. For subscription through an endowment insurance or an investment savings account, please contact your nominee. Application for subscription without preferential rights in other respects is done by electronic subscription with Bank ID on Mangold's website emission.mangold.se.

Advisors

Mangold Fondkommission AB is acting as financial advisor to Alzinova in connection with the Rights Issue. Fredersen Advokatbyrå AB is acting as legal advisor to the Company in connection with the Rights Issue.

For more information, please contact:

Tord Labuda, CEO
E-mail: info@alzinova.com

About Alzinova AB

Alzinova AB is a Swedish biopharmaceutical company in clinical development specializing in the treatment of Alzheimer's disease, where the starting point is to attack toxic amyloid-beta oligomers. The lead candidate ALZ-101 is a therapeutic vaccine against Alzheimer's disease. Alzinova's patented A β CC peptide technology makes it possible to develop disease-modifying treatments that target the toxic amyloid-beta oligomers that are central to the onset and development of the disease with great accuracy. From a global perspective, Alzheimer's disease is one of the most common and devastating neurological diseases, with around 40 million affected today. Based on the same technology, the Company is also developing the antibody ALZ-



201, which is currently in preclinical development, and the goal is to further expand the pipeline. The Company's Certified Adviser on Nasdaq First North Growth Market is Mangold Fondkommission AB. For more information about Alzinova, please visit: www.alzinova.com.

Important Information

The publication, disclosure, or distribution of this press release may be subject to legal restrictions in certain jurisdictions, and persons in the jurisdictions where this press release has been disclosed or distributed should inform themselves of and comply with such legal restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with applicable regulations in the respective jurisdiction. This press release does not constitute an offer to sell or an invitation regarding an offer to acquire or subscribe for securities issued by the Company in any jurisdiction where such an offer or invitation would be unlawful.

This press release is not a prospectus within the meaning of Regulation (EU) 2017/1129 (the "Prospectus Regulation") and has not been approved or reviewed by any regulatory authority in any jurisdiction. Furthermore, this press release does not constitute a document in the form prescribed by Annex IX of the Prospectus Regulation. The invitation to relevant persons to subscribe for shares in Alzinova is made solely through the Disclosure Document published by the Company on 15 April 2025 on the Company's website, www.alzinova.com. The Disclosure Document does not constitute a prospectus as defined in the provisions of the Prospectus Regulation and has neither been reviewed nor approved by the Swedish Financial Supervisory Authority. The offer in the Disclosure Document is exempt from the prospectus requirement pursuant to Article 1.4 db of the Prospectus Regulation and, for this reason, the Disclosure Document has been prepared in accordance with Annex IX of the Prospectus Regulation. Any investment decision should, in order for an investor to fully understand the potential risks and rewards associated with the decision to participate in the Rights Issue, be made solely based on the information contained in the Disclosure Document. Therefore, an investor is recommended to read the entire Disclosure Document.

Within the European Economic Area ("EEA"), no public offering of shares, warrants, or other securities (the "Securities") is made in any country other than Sweden. In other member states of the European Union ("EU"), such an offer of Securities may only be made in accordance with an exemption under the Prospectus Regulation (EU) 2017/1129. In other EEA countries that have implemented the Prospectus Regulation into national law, such an offer of Securities may only be made in accordance with an exemption under the Prospectus Regulation and in accordance with each relevant implementing measure. In other EEA countries that have not implemented the Prospectus Regulation into national law, such an offer of Securities may only be made in accordance with an applicable exemption under national legislation.

This press release does not constitute an offer to acquire or subscribe for securities in the United States. The Securities referred to herein may not be sold in the United States without registration or without applying an exemption from registration under the applicable U.S. Securities Act of 1933 (the "Securities Act") or the securities laws of any state or other jurisdiction in the United States, and may not be offered or sold in the United States without registration, an exemption



from, or in a transaction not subject to the registration requirements of the Securities Act. There is no intention to register any Securities referred to herein in the United States or to make a public offering of such Securities in the United States. The information in this press release may not be disclosed, published, copied, reproduced, or distributed, directly or indirectly, in whole or in part, in or to the United States, Canada, Australia, New Zealand, South Africa, South Korea, Switzerland, Singapore, Japan, Hong Kong, Russia, Belarus, or any other jurisdiction where such disclosure, publication, or distribution of this information would violate applicable regulations or where such an action is subject to legal restrictions or would require additional registration or actions other than those required under Swedish law. Actions contrary to this instruction may constitute a violation of applicable securities laws.

In the United Kingdom, this press release and any other material related to the Securities referred to herein are being distributed and directed only to, and any investment or investment activity to which this press release relates is available only to and will be engaged in only with, "qualified investors" who are (i) persons having professional experience in investment-related activities falling within the definition of "investment professionals" in Article 19(5) of the UK Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (ii) high-net-worth entities as referred to in Article 49(2)(a)–(d) of the Order (all such persons together being referred to as "relevant persons"). Any investment or investment activity to which this press release relates in the United Kingdom is only available to relevant persons and will be undertaken only with relevant persons. Persons who are not relevant persons should not act based on this press release or rely on its contents.

The Company assesses that it conducts a business of strategic interest under the Act (2023:560) on the Review of Foreign Direct Investments (the "FDI Act"). In accordance with the FDI Act, the Company must inform potential investors that its operations may fall within the scope of the regulation and that the investment may be subject to a notification requirement. If an investment is subject to notification, it must be reported to the Inspectorate of Strategic Products (ISP) before being completed. An investment may be subject to notification if the investor, any entity within its ownership structure, or any party on whose behalf the investor is acting, following the completion of the investment, holds voting rights corresponding to or exceeding any of the thresholds of 10, 20, 30, 50, 65, or 90 percent of the total number of votes in the Company. The investor may be subject to an administrative sanction fee if a notifiable investment is carried out before ISP has either: i) decided to take no action on the notification, or ii) approved the investment. Each shareholder should consult an independent legal advisor regarding the potential applicability of the FDI Act in relation to the Rights Issue for the individual shareholder.

This press release does not identify, nor claim to identify, any risks (direct or indirect) associated with an investment in new shares. This press release does not constitute an invitation to underwrite, subscribe for, acquire, or transfer securities in any jurisdiction. This press release does not constitute a recommendation for any investors' decisions regarding the Rights Issue. Each investor or potential investor should conduct their own investigation, analysis, and evaluation of the business and the information described in this press release and all publicly



available information. The price and value of the securities may decrease as well as increase. Past performance does not serve as guidance for future results. Neither the content of the Company's website nor any other website accessible through hyperlinks on the Company's website is incorporated into or forms part of this press release.

Attachments

The subscription period in Alzinovas rights issue of shares starts today